814 Cutaneous immune-related adverse events are protective of mortality in patients treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study

• Nicole LeBoeuf,
• Leyre Zubiri,
• Kerry Reynolds,
• Vartan Pahalyants,
• Yevgeniy Semenov,
• Vivek Naranbhai,
• Alexander Gusev,
• Shawn Kwatra,
• Thomas Le,
• Bruce Tiu,
• Pearl Ugwu-Dike,
• Jayhyun Seo,
• Kimberly Tang,
• Neel Raval,
• Maryam Asgari

Affiliations

Nicole LeBoeuf

4Brigham and Women’s Hospital, Bostom, MA, USA

Leyre Zubiri

Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Kerry Reynolds

3Massachusetts General Hospital, Boston, MA, USA

Vartan Pahalyants

Harvard Medical School, Boston, Massachusetts, USA

Yevgeniy Semenov

2Massachusetts General Hospital, Boston, MA, USA

Vivek Naranbhai

Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Alexander Gusev

Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Shawn Kwatra

5Johns Hopkins University, Baltimore, MD, USA

Thomas Le

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Bruce Tiu

1Harvard Medical School, Boston, MA, United States

Pearl Ugwu-Dike

2Massachusetts General Hospital, Boston, MA, United States

Jayhyun Seo

2Massachusetts General Hospital, Boston, MA, United States

Kimberly Tang

2Massachusetts General Hospital, Boston, MA, United States

Neel Raval

2Massachusetts General Hospital, Boston, MA, United States

Maryam Asgari

3Harvard Medical School, Boston, MA, United States